More than 50 companies with ambitions to bring psychedelics to market have gone public since early 2020—a clear sign that mind-altering substances once relegated to college dorm rooms and underground nightclubs are gaining mainstream acceptance.

But the legal chiefs and other executives behind those companies—which are pursuing treatments for a range of mental health disorders, from addiction and depression to anxiety and PTSD—say they continue to battle stigmas and misconceptions that threaten to limit access to capital and hold back growth.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]